Anti-SLC34A2 (Lifastuzumab)-McMMAF
Product Sizes
Get quote
£ POA
HY-171737-1EACH
About this Product
- SKU:
- HY-171737
- Application:
- Antibody Microarray
- Extra Details:
- Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab (HY-P99970) conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part McMMAF (HY-15578). Anti-SLC34A2 (Lifastuzumab)-McMMAF induces apoptosis and can be used in cancer research[1][2].
- References:
- [1]Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923.|[2]Tai YT, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15;123(20):3128-38.
- Research Area:
- Cancer
- Shipping Conditions:
- Ambient
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Conjugated Protein
